alzheimers-disease

Gulino R (2016) Neuroplasticity and repair in rodent neurotoxic models of spinal motoneuron disease. Neural Plast 2016:2769735. doi: 10.1155/2016/2769735

Summary: TDP-43 (Transactive response DNA-binding protein) is a highly conserved nuclear protein that binds both DNA and RNA. It has been found in cytoplasmic protein aggregates of patients with conditions such as amyotrophic lateral sclerosis and Alzheimer’s disease. In this work the authors examine the role of TDP-43 in spinal cord plasticity. Mice received bilateral 3-μg injections of CTB-SAP (Cat. #IT-14) into the lateral and medial gastrocnemius muscles. The results indicate that motor performance is dependent on expression of synapsin-I, which in turn may be dependent on TDP-43.

Related Products: CTB-SAP (Cat. #IT-14)

Chen Y, Pan C, Xuan A, Xu L, Bao G, Liu F, Fang J, Long D (2015) Treatment efficacy of NGF nanoparticles combining neural stem cell transplantation on Alzheimer’s Disease model rats. Med Sci Monit 21:3608-3615. doi: 10.12659/msm.894567

Summary: NSC (neural stem cell) transplants into animals have been shown to compensate for the loss of cholinergic cells in the basal forebrain, a hallmark of Alzheimer’s disease. One hurdle to overcome is the actuation of NSC differentiation into the specific replacement cells needed. NGF has been shown to induce this differentiation, but it has a very short half-life and does not permeate tissue very effectively. In this work the authors administered 5 mcl of icv 192-IgG-SAP (Cat. #IT-01) to rats, followed by a graft of NCSs in the presence of NGF nanoparticles with a polymer coating. Rats receiving both NCSs and NGF nanoparticles showed significantly improved memory and learning functions as compared to control animals.

Related Products: 192-IgG-SAP (Cat. #IT-01)

Li T, Yu Y, Cai H (2015) Effects of brain-derived neurotrophic factor-pretreated neuron stem cell transplantation on Alzheimer’s disease model mice. Int J Clin Exp Med 8:21947-21955.

Summary: In order to generate the AD mouse model, mu p75-SAP (1-1.2 μg/μL)  was injected to the bilateral icv areas.

Related Products: mu p75-SAP (Cat. #IT-16)

Carnes B, DeLacalle S (2015) Compensatory cortical sprouting across the lifespan of the rat. Neuroscience 2015 Abstracts 391.10/C34. Society for Neuroscience, Chicago IL.

Summary: To investigate the plastic capacity of the cholinergic system in a partial animal model of Alzheimer’s disease, adult and aged rats received unilateral lesions of the horizontal diagonal band of Broca (HDB) using the cholinergic-specific toxin 192-IgG-saporin. The rats were sacrificed at 2, 4, 8, 12, or 24 weeks post lesion. Immuno- and histochemical techniques were used to quantify the effects of the lesion. Tissues were stained using an acetylcholinesterase technique. A 230µm by 200µm grid was used to indirectly measure the density of cholinergic fibers in the Entorhinal Cortex (EC). We compared our data to a young (3 month old) control group (Hartonian, 2005) in which the maximal loss of fiber density occurred by 8 weeks post-lesion and recovered to 75% of the intact contralateral EC by 12 weeks. All groups (young adult: 12-15; adult: 18; aged: 24-27 month old rats at the start of the experiment) exhibited a decrease in cortical fiber density after the lesion, which was more pronounced in the young adult group. All groups showed a recovery in fiber density to 60-80% of the intact side by 24 weeks post lesion. Interestingly, the loss occurred faster and more intense in the young adult group (to 25% of the intact side at 8 weeks post-lesion) than in the older ones (to 60% of the intact side by week 12 post lesion). Twenty four weeks after the lesion, the young adult group had recovered fiber density to 70%. The adult group also reached 70%, and the aged group reached 80% of the contralateral intact side. We conclude that following a cholinergic specific lesion, a compensatory mechanism is activated in the basal forebrain such that surviving neurons, projecting to the same target, are able to extend terminals and occupy the denervated area. It remains to be investigated whether the sprouts are able to establish proper synaptic connections and make a functional recovery.

Related Products: 192-IgG-SAP (Cat. #IT-01)

Nair DV, Al-Badri MM, Peng H, Pachego-Quinto J, Eckman CB, Iacono D, Eckman EA (2015) Preliminary investigation on the antidepressive effect of chronic oxotremorine treatment in a rodent model of Alzheimer’s disease. Neuroscience 2015 Abstracts 40.29/C34. Society for Neuroscience, Chicago IL.

Summary: Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the rate of progression varies from individual to individual. A great deal of evidence supports the idea that depression and other neuropsychiatric conditions co-exist with cognitive decline. However, the neurobiological basis of these symptoms and their influence on the clinical course of AD remain unclear. Our lab has shown previously that the 192-IgG saporin rat model of AD-like basal forebrain cholinergic cell loss exhibits a depression-like phenotype that develops months after the well-described impairment in spatial working memory. Furthermore, we have shown that chronic intracerebroventricular administration of the muscarinic agonist oxotremorine reverses both spatial working memory deficits and the depression-like behavior triggered by cholinergic denervation, and induces hippocampal neurogenesis. Current experiments are focused on determining additional pathological correlates of depression in this model and how they may be modulated by muscarinic agonists. To induce AD-like basal forebrain cholinergic cell loss, adult female Sprague Dawley rats were injected intracerebroventricularly (icv) with the immunotoxin 192-IgG-saporin (SAP) or saline as control (SHAM). After a 5 week recovery period, the rats received either 2 or 6 weeks of icv infusion of either oxotremorine or vehicle (saline) via osmotic minipump. Behavioral testing to assess the depressive phenotype was carried out using the sucrose consumption test every 2 weeks during oxotremorine treatment. The phenotype was further confirmed by forced swim test. The levels of ChAT, tryptophan hydroxylase (TPH), muscarinic receptors and FosB and ΔFosB were assessed in the hippocampus, basal forebrain, and orbitofrontal cortex by western blot and immunohistochemistry. Our preliminary results show increases in TPH, M1 receptors and FosB in the hippocampus, basal forebrain, and orbitofrontal cortex of a subset of treated animals, but no changes ChAT or ΔFosB. Further experiments are in progress to determine if there are changes in the expression of these and additional proteins in other brain regions including the nucleus accumbens, an area involved in activational aspects of motivation which also contributes to behavioral disorders such as to depression. The results of these studies may provide new insight in understanding the molecular basis of depression and antidepressant action of oxotremorine thereby defining new targets for possible therapeutic intervention for depressive symptoms in AD.

Related Products: 192-IgG-SAP (Cat. #IT-01)

Kim T, Thankachan S, McKenna J, McNally J, Yang C, Choi J, Chen L, Kocsis B, Deisseroth K, Strecker R, Basheer R, Brown R, McCarley R (2015) Cortically projecting basal forebrain parvalbumin neurons regulate cortical gamma band oscillations. Proc Natl Acad Sci U S A 112:3535-3540. doi: 10.1073/pnas.1413625112

Summary: Measurements of cortical EEG capture gamma band oscillations (GBO). Abnormalities in these GBO have been found in some neuropsychiatric disorders such as Alzheimer’s disease and schizophrenia. The authors analyzed GBO neuronal groups by administering 650-ng bilateral icv injections of mu p75-SAP (Cat. #IT-16) to mice to determine the role of basal forebrain cholinergic neurons in the generation of GBO. The results indicate GABAergic basal forebrain neurons containing parvalbumin were important for GBO integrity, but cholinergic neurons in the basal forebrain were not involved.

Related Products: mu p75-SAP (Cat. #IT-16)

Nair DV, Al-Badri MM, Peng H, Schenkman N, Pacheco-Quinto J, Eckman CB, Iacono D, Eckman EA (2014) Chronic oxotremorine treatment ameliorates depressive phenotype in a rodent model of Alzheimer’s disease. Neuroscience 2014 Abstracts 670.03. Society for Neuroscience, Washington, DC.

Summary: Alzheimer’s disease (AD) is a progressive neurodegenerative condition that is characterized by changes to brain structure and function. It is estimated that depression and other neuropsychiatric symptoms occur in up to 90% of AD patients, yet the neurobiological basis of these symptoms and their influence on the clinical course of AD remain unclear. Using a rat model of AD-like basal forebrain cholinergic cell loss, our lab has previously shown that central administration of a muscarinic receptor agonist, oxotremorine, for 4 weeks could induce hippocampal neurogenesis and reverse the spatial working memory deficit triggered by cholinergic denervation. Preliminary experiments conducted with this model in our lab also revealed a depressive phenotype emerging between 11 and 15 weeks after cholinergic denervation. The depressive phenotype was detected using a sucrose consumption test and further confirmed by forced swim test. The goal of the present study was to determine whether effects of chronic oxotremorine treatment could ameliorate the depressive phenotype observed after selective cholinergic cell loss in the basal forebrain. Adult female Sprague Dawley rats were injected intracerebroventricularly (icv) with the immunotoxin 192-IgG-saporin (SAP), to induce AD-like basal forebrain cholinergic cell loss. After a 5 week recovery period, the rats then received 8 weeks of icv infusion of either oxotremorine or vehicle (saline) via osmotic minipump. Behavioral testing to assess the depressive phenotype was carried out using the sucrose consumption test every 2 weeks during oxotremorine treatment. The phenotype was further confirmed by forced swim test. Biochemical analysis of a range of markers including tryptophan hydroxylase, the rate limiting enzyme for synthesis of serotonin, was performed after extraction of the brains following the behavioral tests. Results of these experiments demonstrate that oxotremorine treatment prevents the development of the depressive phenotype in SAP-lesioned rats. A number of oxotremorine-treated rats showed increases in tryptophan hydroxylase, suggesting a possible mechanism for the improved behavioral phenotype Based on these data, we propose that 192-IgG saporin lesioned rats may be an effective model for studying the pathophysiology and therapeutic modulation of age- and neurodegeneration-related neuropsychiatric symptoms such as depression.

Related Products: 192-IgG-SAP (Cat. #IT-01)

Köppen JR, Stuebing SS, Sieg M, Blackwell AA, Blankenship P, Grisley ED, Cheatwood JL, Wallace DG (2014) Is selective hippocampal cholinergic deafferentation sufficient to produce temporally graded retrograde amnesia?. Neuroscience 2014 Abstracts 749.20. Society for Neuroscience, Washington, DC.

Summary: Dementia of the Alzheimer’s type (DAT) is a neurodegenerative disorder marked by degeneration of basal forebrain structures and is associated with significant mnemonic deficits. The current study used a rat string-pulling task to evaluate whether selective cholinergic deafferentation of the hippocampus is sufficient to produce temporally graded retrograde amnesia. Female rats were pre-trained to pull strings to obtain reinforcement (cashew). Subsequently, rats were trained to discriminate between two scented strings. One scented string was consistently reinforced (+A), while the other scented string was never reinforced (B). After rats met criterion, they either waited two weeks (recent) or six weeks (remote) prior to receiving a sham surgery or infusion of 192-IgG-Saporin into the medial septum. Two weeks later rats were given four days of reversal training during which they experienced the same scented strings; however, the cashew was at the end of the string that was not previously reinforced. Following reversal training, rats were trained on a novel discrimination (+C/D). The results of the current study are consistent with selective cholinergic deafferentation of the hippocampus being sufficient to produce retrograde amnesia that was not temporally graded. First, all rats met criterion in a similar number of days. Rats receiving infusion of 192-IgG-Saporin into the medial septum had a higher number of correct responses during reversal training, relative to sham rats; however, no group differences were observed between recent and remote groups. Next, there were no group differences in the ability to learn a new discrimination. Finally, no group differences we observed in the latency to approach and pull up the string. The results were not caused by deficits in motivation or motor function, but they do reflect impairments in mnemonic function. The current study provides a novel behavioral assessment technique that models the retrograde amnesia characteristics observed in DAT.

Related Products: 192-IgG-SAP (Cat. #IT-01)

Van Kampen JM, Kay DG, Maelicke A (2014) The galantamine prodrug, Memogain®, reverses deficits in hippocampal neurogenesis associated with the loss of basal forebrain cholinergic neurons. Neuroscience 2014 Abstracts 789.21. Society for Neuroscience, Washington, DC.

Summary: Loss of basal forebrain cholinergic innervation of the hippocampus and severe neuronal loss within the hippocampal CA1 region are early hallmarks of Alzheimer’s disease (AD), and are strongly correlated with cognitive status. This loss of cholinergic innervation is a key factor underlying alterations in hippocampal neurogenesis, which are also characteristic of AD. We have previously reported the effects of various cholinergic compounds on hippocampal neurogenesis indicating that acetylcholine serves as a potent neurogenic regulator. Memogain® (GLN 1062) is an inactive galantamine pro-drug with 15 fold higher brain availability than galantamine. It is designed to provide improved blood brain barrier penetration, greater potency, and fewer side effects than the cholinesterase inhibitors currently used for the treatment of Alzheimer’s dementia. This would serve both to promote patient adherence and permit the use of higher doses. Galantamine is unique among the cholinesterase inhibitors in that it also has allosteric actions at α-7 nicotinic receptors, activation of which has been linked to both disease-modifying and cognitive enhancing effects, as well as effects on hippocampal cell proliferation. Here, we describe the neurogenic actions of Memogain® in a rodent model of cholinergic depletion. Infusion of the immunotoxin, 192IgG saporin (SAP), used to induce selective basal forebrain cholinergic cell loss reminiscent of that found in AD, resulted in a pronounced loss of basal forebrain cholinergic neurons and hippocampal ChAT fiber density. Consistent with earlier reports, SAP-lesioned animals had significantly fewer BrdU+ and PCNA+ cells in both the dentate gyrus and CA1 region of the hippocampus, when compared to sham-operated control animals. These animals also displayed significant impairments in spatial working memory, as assessed by a T-maze and the radial arm maze. By contrast, animals treated with Memogain® displayed a restoration of hippocampal cell proliferation, increased neuronal cell counts, normalized neuronal migration, and improvements in cognitive function. Thus, the beneficial effects of Memogain® may extend beyond acute cognitive enhancement, to include disease modification through support of hippocampal neurogenesis.

Related Products: 192-IgG-SAP (Cat. #IT-01)

Tiwari D, Haynes J, Short J, Pouton C (2014) Investigating the potential of stem cell based therapy in an immunotoxin mouse model of Alzheimer’s disease. Neuroscience 2014 Abstracts 295.14. Society for Neuroscience, Washington, DC.

Summary: Purpose: To characterize a dual reporter embryonic stem (ES) cell line and validate an immunotoxin mouse model of Alzheimer’s disease for future transplantation experiments. Methods: A dual (mcherry and Lhx8+) reporter ES cell line was derived from E14Tg2a mouse ES cells assessed for differentiation capability and characterized using immunocytochemistry. For the immunotoxin model, 6-8 weeks C57BL/6 male mice (n = 12) were treated with bilateral intracerebroventricular injections of saline or mu-p75-saporin toxin (0.4µg/µl/mouse) to cause cholinergic neuronal lesions. Mice were cognitively assessed using a novel water maze (WM) protocol and novel object recognition (NOR) paradigm. Immunohistochemistry was performed to detect toxin dependent neuronal loss. Results: A significant difference in learning the WM task was observed during cued and spatial trials, with toxin-treated mice showing longer latency to platform than controls (two way ANOVA; p<0.01). Also performance during probe trial was significantly reduced in treated mice (t-test; p<0.05), indicating memory loss by toxin. No memory impairment was detected using the NOR test. Immunohistochemistry for choline acetyltransferase (ChAT) confirmed a significant loss (p<0.001; t test) of cholinergic neurons in the medial septum. These data indicate that the model is appropriate for future transplantation studies. FACS analysis of reporter cell line showed a small population of Lhx8+ cells at day 6 and 10 of differentiation. Immunocytochemistry for ChAT on day 18 cells revealed few cholinergic positives neurons as compared to wild type controls. Conclusion: Literature suggests a possible role of Lhx8 in cholinergic development and these cells are being further investigated by transplantation.

Related Products: mu p75-SAP (Cat. #IT-16)